
Exelixis (EXEL) Stock Forecast & Price Target
Exelixis (EXEL) Analyst Ratings
Bulls say
Exelixis is expecting a positive uptick in sentiment for the potential approval of Zanzalintinib plus Atezolizumab (Tecentriq) in patients with non-microsatellite instability-high colorectal cancer on December 3, 2026, in addition to multiple upcoming catalysts in ongoing trials for other indications. The company has shown strong growth in end-user demand for its lead product Cabometyx, and its stock buyback program and disciplined control of expenses also provide potential for earnings uptick in the future. The company's financials are strong, with a DCF-based firm value of approximately $13.9B and a 12-month price objective of $56 per share, based on a 15x multiple on the estimated FY26 non-GAAP EPS of $3.66. The company's partnerships and pipeline expansion also offer potential for future growth and re-rating of the stock.
Bears say
Exelixis is currently facing numerous risks in the biotechnology sector, including commercial risks with Cabometyx sales being hindered by the introduction of competitors' products, the possibility of unfavorable data from ongoing clinical programs, and the potential for generic erosion of their existing blockbuster drug, cabozantinib. Additionally, their reliance on external funding for their research and development could create challenges in the capital-raising environment. However, Exelixis's strong cash flow and aggressive buyback program may provide support for their stock in the short term.
This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.
Exelixis (EXEL) Analyst Forecast & Price Prediction
Start investing in Exelixis (EXEL)
Order type
Buy in
Order amount
Est. shares
0 shares